Haemonetics Corporation 10-K Summary
Business Context and Reporting Period
Company: Haemonetics Corporation
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended March 30, 1996
Business Overview: Haemonetics designs, manufactures, and markets automated systems for the collection, processing, and surgical salvage of blood. The company operates in a single industry segment with four primary therapeutic markets: surgical blood salvage, blood component therapy, automated red cell collection, and plasma collection. Products are sold to hospitals, blood banks, and commercial plasma firms in over 50 countries.
Key Financial Metrics
| Metric (in thousands) | Fiscal 1996 | Fiscal 1995 |
|---|---|---|
| Net Revenues | $278,216 | $262,416 |
| Gross Profit | $154,613 | $144,855 |
| Gross Margin | 55.6% | 55.2% |
| Operating Income | $54,371 | $52,378 |
| Net Income | $35,925 | $33,645 |
| Earnings Per Share | $1.30 | $1.18 |
| Cash Flow from Operations | $54,810 | $15,628 |
| Total Debt | $18,534 | $33,392 |
| Working Capital | $112,440 | $108,459 |
| Current Ratio | 3.4 | 3.2 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 6.0% to $278.2 million. Worldwide disposable sales grew 7.7%, while equipment sales decreased 4.3% internationally, offset by domestic growth.
- Profitability: Gross profit margin improved to 55.6% from 55.2%, driven by favorable manufacturing variances. Net income rose 6.8% to $35.9 million.
- Debt Reduction: Total debt decreased significantly by approximately 44.5% (from $33.4 million to $18.5 million) as the company paid down $12.8 million in revolving credit agreements.
- Cash Flow: Operating cash flow surged to $54.8 million from $15.6 million in the prior year, reflecting improved working capital management and profitability.
- Acquisitions: The company acquired DHL Laboratories assets in August 1995 for $6.2 million to expand capabilities in storage and anticoagulant solutions.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Product Pipeline: The company received FDA clearance in early 1996 for new protocols including two-unit red blood cell collection, leukocyte collection, and double single-donor platelet protocols. These advancements aim to improve efficiency and address shrinking donor populations.
- Capital Allocation: The Board approved an additional 1,000,000 share repurchase program. Approximately 1.49 million shares remain available for repurchase under combined programs.
- Liquidity: Management believes committed bank lines and internally generated funds are sufficient to meet future needs.
Risks and Contingencies:
- Regulatory: Products are subject to strict FDA and international regulations. Delays in approvals or changes in regulations could impact operations.
- Competition: The market is highly competitive with larger rivals (e.g., Baxter, COBE) possessing greater financial resources.
- Product Liability: As with all medical device manufacturers, the company faces potential litigation regarding patient injury or death, which could impact reputation and insurance costs.
- Supply Chain: Certain parts are sourced from single suppliers; interruptions could temporarily affect production.
Investor Verification Checklist
- Disposable Sales Sustainability: Verify if the 7.7% growth in disposable sales (88% of revenue) can be sustained given the installed base and utilization rates.
- International Equipment Sales: Monitor the trend of declining international equipment sales and the impact of national self-sufficiency programs in Europe and Japan.
- Debt Covenants: Confirm continued compliance with debt covenants regarding tangible net worth and debt-to-net-worth ratios.
- Regulatory Approvals: Track the commercialization timeline and adoption rates of the new FDA-cleared protocols (red cell, leukocyte, platelet).
- Stock Repurchase Execution: Assess the pace and pricing of the remaining 1.49 million shares available for repurchase.